Terms: = Lung cancer AND FUS, P35637, 2521, ENSG00000089280, TLS/CHOP, FUS-CHOP, CHOP, FUS1, TLS AND Clinical Outcome
9 results:
1. Complete pathological remission and tertiary lymphoid structures are associated with the efficacy of resectable NSCLC receiving neoadjuvant chemoimmunotherapy: A double-center retrospective study.
Liu Y; Xiong L; Chen Y; Cai R; Xu X; Wang T; Guo Y; Ruan L; Fang Y; Zhang Q; Shen B; Ye J; Zhou G
Hum Vaccin Immunother; 2023 Dec; 19(3):2285902. PubMed ID: 38010104
[TBL] [Abstract] [Full Text] [Related]
2. Regulatory T cells infiltrate the tumor-induced tertiary lymphoïd structures and are associated with poor clinical outcome in NSCLC.
Devi-Marulkar P; Fastenackels S; Karapentiantz P; Goc J; Germain C; Kaplon H; Knockaert S; Olive D; Panouillot M; Validire P; Damotte D; Alifano M; Murris J; Katsahian S; Lawand M; Dieu-Nosjean MC
Commun Biol; 2022 Dec; 5(1):1416. PubMed ID: 36566320
[TBL] [Abstract] [Full Text] [Related]
3. Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in lung cancer Patients.
Germain C; Devi-Marulkar P; Knockaert S; Biton J; Kaplon H; Letaïef L; Goc J; Seguin-Givelet A; Gossot D; Girard N; Validire P; Lefèvre M; Damotte D; Alifano M; Lemoine FM; Steele KE; Teillaud JL; Hammond SA; Dieu-Nosjean MC
Front Immunol; 2021; 12():626776. PubMed ID: 33763071
[TBL] [Abstract] [Full Text] [Related]
4. Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure.
Lin Z; Huang L; Li S; Gu J; Cui X; Zhou Y
Sci Rep; 2020 Dec; 10(1):21530. PubMed ID: 33299035
[TBL] [Abstract] [Full Text] [Related]
5. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers.
Dieu-Nosjean MC; Giraldo NA; Kaplon H; Germain C; Fridman WH; Sautès-Fridman C
Immunol Rev; 2016 May; 271(1):260-75. PubMed ID: 27088920
[TBL] [Abstract] [Full Text] [Related]
6. Association of polymorphisms in translesion synthesis genes with prognosis of advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Zhang X; Chen Q; Chen J; He C; Mao J; Dai Y; Yang X; Hu W; Zhu C; Chen B
J Surg Oncol; 2016 Jan; 113(1):17-23. PubMed ID: 26611653
[TBL] [Abstract] [Full Text] [Related]
7. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer.
Germain C; Gnjatic S; Tamzalit F; Knockaert S; Remark R; Goc J; Lepelley A; Becht E; Katsahian S; Bizouard G; Validire P; Damotte D; Alifano M; Magdeleinat P; Cremer I; Teillaud JL; Fridman WH; Sautès-Fridman C; Dieu-Nosjean MC
Am J Respir Crit Care Med; 2014 Apr; 189(7):832-44. PubMed ID: 24484236
[TBL] [Abstract] [Full Text] [Related]
8. Immune infiltration in human cancer: prognostic significance and disease control.
Fridman WH; Galon J; Dieu-Nosjean MC; Cremer I; Fisson S; Damotte D; Pagès F; Tartour E; Sautès-Fridman C
Curr Top Microbiol Immunol; 2011; 344():1-24. PubMed ID: 20512556
[TBL] [Abstract] [Full Text] [Related]
9. When is hilar uptake of 67Ga-citrate indicative of residual disease after chop chemotherapy?
Frohlich DE; Chen JL; Neuberg D; Kehoe KM; Van den Abbeele AD
J Nucl Med; 2000 Feb; 41(2):269-74. PubMed ID: 10688110
[TBL] [Abstract] [Full Text] [Related]
